1. Home
  2. VNRX vs JSPR Comparison

VNRX vs JSPR Comparison

Compare VNRX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.16

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.86

Market Cap

23.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VNRX
JSPR
Founded
N/A
2018
Country
United States
United States
Employees
N/A
22
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
23.1M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
VNRX
JSPR
Price
$0.16
$0.86
Analyst Decision
Strong Buy
Buy
Analyst Count
5
11
Target Price
$2.00
$15.50
AVG Volume (30 Days)
17.2M
562.8K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
38.00
N/A
EPS
N/A
N/A
Revenue
$1,727,384.00
N/A
Revenue This Year
$479.89
N/A
Revenue Next Year
$538.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.04
N/A
52 Week Low
$0.15
$0.62
52 Week High
$0.94
$7.19

Technical Indicators

Market Signals
Indicator
VNRX
JSPR
Relative Strength Index (RSI) 33.98 39.95
Support Level N/A N/A
Resistance Level $0.27 $1.44
Average True Range (ATR) 0.02 0.11
MACD -0.00 -0.00
Stochastic Oscillator 5.66 43.95

Price Performance

Historical Comparison
VNRX
JSPR

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: